ATE389659T1 - Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors - Google Patents

Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors

Info

Publication number
ATE389659T1
ATE389659T1 AT02740691T AT02740691T ATE389659T1 AT E389659 T1 ATE389659 T1 AT E389659T1 AT 02740691 T AT02740691 T AT 02740691T AT 02740691 T AT02740691 T AT 02740691T AT E389659 T1 ATE389659 T1 AT E389659T1
Authority
AT
Austria
Prior art keywords
ampa receptor
benzoxazepine derivatives
receptor stimulators
stimulators
benzoxazepine
Prior art date
Application number
AT02740691T
Other languages
English (en)
Inventor
Simon James Anthony Grove
Mingqiang Zhang
Mohammad Shahid
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Application granted granted Critical
Publication of ATE389659T1 publication Critical patent/ATE389659T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02740691T 2001-06-11 2002-06-05 Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors ATE389659T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01202215 2001-06-11

Publications (1)

Publication Number Publication Date
ATE389659T1 true ATE389659T1 (de) 2008-04-15

Family

ID=8180450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02740691T ATE389659T1 (de) 2001-06-11 2002-06-05 Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors

Country Status (29)

Country Link
US (2) US7307073B2 (de)
EP (1) EP1399450B1 (de)
JP (1) JP4435561B2 (de)
KR (1) KR100863255B1 (de)
CN (1) CN1257908C (de)
AR (1) AR036092A1 (de)
AT (1) ATE389659T1 (de)
AU (1) AU2002314144B2 (de)
BR (1) BR0210222A (de)
CA (1) CA2450274C (de)
CO (1) CO5550447A2 (de)
CZ (1) CZ300052B6 (de)
DE (1) DE60225689T2 (de)
EC (1) ECSP034891A (de)
ES (1) ES2301651T3 (de)
HR (1) HRP20031007A2 (de)
HU (1) HUP0400154A3 (de)
IL (2) IL158905A0 (de)
IS (1) IS2526B (de)
MX (1) MXPA03011563A (de)
NO (1) NO328705B1 (de)
NZ (1) NZ529670A (de)
PE (1) PE20030097A1 (de)
PL (1) PL366721A1 (de)
RU (1) RU2279434C2 (de)
SK (1) SK287150B6 (de)
TW (1) TWI232863B (de)
WO (1) WO2002100865A1 (de)
ZA (1) ZA200309382B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400196A3 (en) 2001-06-14 2007-05-02 Organon Nv (pyrido/thieno)[f]oxazepin-5-one derivatives, their use and pharmaceutical compositions containing them
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
CA2772691C (en) * 2009-09-28 2017-10-03 F. Hoffmann-La Roche Ag Benzoxazepin pi3k inhibitor compounds and methods of use
FR2964969B1 (fr) 2010-09-16 2012-08-24 Servier Lab Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
US20190112300A1 (en) 2016-03-29 2019-04-18 Arnold Stan Lippa Compositions And Methods For Treating Attention Deficit Disorders
CN116751200A (zh) 2016-11-07 2023-09-15 爱彼特生物制药公司 含有取代的吡啶酮的三环化合物以及使用其的方法
US11702427B2 (en) 2018-03-12 2023-07-18 Arbutus Biopharma Corporation Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
EP3773584A4 (de) 2018-04-12 2022-01-05 Arbutus Biopharma Corporation Verfahren zur herstellung von substituierten pyridinonhaltigen tricyclischen verbindungen
BR112021009770A2 (pt) 2018-11-22 2021-08-17 Fujian Cosunter Pharmaceutical Co., Ltd. forma cristalina de inibidor de antígeno de superfície de hepatite b
EP4121072A1 (de) * 2020-03-20 2023-01-25 Amathus Therapeutics, Inc. Cyclische sulfonamidderivate als trap1-modulatoren und verwendungen davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1238719A (de) 1968-11-01 1971-07-07
EP1156043B1 (de) 1992-07-24 2003-11-12 The Regents Of The University Of California Arzneimittel die den durch AMPA Rezeptoren vermittelten synaptischen Response erhöhen
TR199700587T1 (xx) 1995-01-06 1998-02-21 F. Hoffmann-La Roche Ag Hidroksimetil-imidazodiazepin ve bunlar�n esterleri.
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
ATE303997T1 (de) 1997-06-09 2005-09-15 Pfizer Prod Inc Chinazolin-4-on ampa antagonisten
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
CA2320354A1 (en) * 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
US6124278A (en) 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
DE60225689D1 (de) 2008-04-30
CO5550447A2 (es) 2005-08-31
HUP0400154A2 (hu) 2004-07-28
NO20035486D0 (no) 2003-12-10
WO2002100865A1 (en) 2002-12-19
IS2526B (is) 2009-07-15
AR036092A1 (es) 2004-08-11
RU2279434C2 (ru) 2006-07-10
US7504390B2 (en) 2009-03-17
IL158905A0 (en) 2004-05-12
ECSP034891A (es) 2004-01-28
CN1257908C (zh) 2006-05-31
BR0210222A (pt) 2004-04-13
KR100863255B1 (ko) 2008-10-15
HRP20031007A2 (en) 2005-10-31
KR20040006030A (ko) 2004-01-16
CA2450274A1 (en) 2002-12-19
AU2002314144B2 (en) 2008-01-31
NZ529670A (en) 2006-02-24
PE20030097A1 (es) 2003-02-08
RU2004100310A (ru) 2005-06-10
JP2004533466A (ja) 2004-11-04
US7307073B2 (en) 2007-12-11
ES2301651T3 (es) 2008-07-01
US20080139529A1 (en) 2008-06-12
EP1399450B1 (de) 2008-03-19
HUP0400154A3 (en) 2007-05-02
MXPA03011563A (es) 2004-03-18
CN1514835A (zh) 2004-07-21
DE60225689T2 (de) 2008-07-17
PL366721A1 (en) 2005-02-07
NO328705B1 (no) 2010-05-03
CZ20033376A3 (en) 2004-04-14
EP1399450A1 (de) 2004-03-24
SK15182003A3 (sk) 2004-05-04
IL158905A (en) 2008-12-29
JP4435561B2 (ja) 2010-03-17
CZ300052B6 (cs) 2009-01-21
US20040171605A1 (en) 2004-09-02
HK1061858A1 (en) 2004-10-08
ZA200309382B (en) 2005-03-02
IS7036A (is) 2003-11-13
CA2450274C (en) 2010-12-21
SK287150B6 (sk) 2010-01-07
TWI232863B (en) 2005-05-21

Similar Documents

Publication Publication Date Title
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE60009116D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60005386D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60015296D1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
ATE332294T1 (de) Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60135239D1 (de) Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
ATE277905T1 (de) 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
DE60308998D1 (de) N-aryl-2-oxazolidinon-5-carbonsäureamide und deren derivate und deren verwendung als antibakterielle mittel
ATE280158T1 (de) 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten
ATE458717T1 (de) Beta-amino-alpha-cyanoacrylate und deren verwendung als herbizide
DE60325493D1 (de) Substituierte 1,4-dipiperidin-4-yl-piperazinderivate und deren verwendung als neurokininantagonisten
DE60335151D1 (de) Pyrimidinderivate und deren Verwendung als CB2-Modulatoren
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
ATE392416T1 (de) Tetrahydrochinolinderivate und deren verwendung als modulatoren des fsh rezeptors
DE60107603D1 (de) Pyrimidinverbindungen und deren verwendung als pestizide
DE60225689D1 (de) Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors
ATE401333T1 (de) 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors
ATE353881T1 (de) 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten
ATE329908T1 (de) Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
ATE361295T1 (de) Substituierte diketopiperazine und deren verwendung als oxytocynantagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1399450

Country of ref document: EP